Nearly two years after Teva Pharmaceutical Industries Ltd.won a high-stakes bidding war to buy the German generics manufacturer ratiopharm Group for $5 billion in order to aggressively build its broad presence in Europe, it is striking a different tone.
Under the leadership of CEO Jeremy Levin, who joined the company in January and became CEO in May, the company...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?